Drugs, Bipolar Disorder, Life Sciences
More Info Needed on Alkermes Drug
Ryan McBride 2/11/09
Alkermes (NASDAQ:ALKS), a Cambridge, MA-based biotech company, says that the FDA has asked the firm’s partner, Johnson & Johnson, for more information about a long-acting version of schizophrenia drug risperidone before the agency decides whether to approve it as supplemental treatment for bipolar disorder. The drug, marketed under the names Risperdal and Consta, garnered U.S. marketing approval in 2003 as a treatment for schizophrenia.
Ryan McBride is Xconomy's correspondent. You can reach him at rmcbride@xconomy.com, or follow him on Twitter at http://twitter.com/Ryan_McBride.
